ArticleMolecular biology reports2026
Dual modulation of Wnt and inflammatory pathways by Gingerenone a inhibits colorectal tumorigenesis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a major global health challenge, driven by aberrant activation of the Wnt/β-catenin pathway and persistent inflammatory signaling. Natural bioactive compounds capable of simultaneously targeting these molecular drivers represent an attractive avenue for safer and more effective chemoprevention. This study aimed to evaluate the anti-carcinogenic potential of Gingerenone A (GinA), a diarylheptanoid derived from ginger, by assessing its effects on Wnt/β-catenin signaling, inflammatory mediators, oxidative stress, and apoptosis during colorectal tumorigenesis.
methodsGinA's effects were assessed using HT29 human colorectal adenocarcinoma cells and a 1,2-dimethylhydrazine (DMH)-induced rat model of CRC. In vitro analyses included MTT cytotoxicity, immunofluorescence, and ELISA assays for β-catenin, APC, COX-2, iNOS, and cleaved caspase-3. In vivo, tumor burden, aberrant crypt foci (ACF), histopathology, immunohistochemistry, oxidative stress (ROS), apoptosis (TUNEL), and serum biochemical parameters were evaluated.
resultsGinA treatment significantly reduced HT29 cell viability in a dose- and time-dependent manner, suppressed β-catenin, COX-2, and iNOS expression, enhanced APC expression and caspase-3 expression and activity, and promoted apoptosis. In DMH-treated rats, GinA markedly decreased tumor incidence, ACF number, and dysplasia severity. Molecular and biochemical analyses revealed restoration of APC, downregulation of β-catenin, Wnt5a, COX-2, and iNOS, reduced ROS accumulation, and normalization of hepatic and renal biomarkers.
conclusionGinA effectively modulates components of the Wnt/β-catenin pathway and inflammatory signaling, exhibiting antioxidant, anti-inflammatory, and pro-apoptotic properties without systemic toxicity. These results position GinA as a multitarget phytochemical with strong potential for colorectal cancer chemoprevention and adjunctive therapy.
Indexed as
Identifiers
42171839What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.